Efficacy and Safety of CosmeRNA-ARI Anti Hair Loss Tonic in Adults With Androgenetic Alopecia
A 24-Week, Double-Blind, Placebo-Controlled, Randomized Human Application Study to Evaluate the Efficacy and Safety of CosmeRNA-ARI Anti Hair Loss Tonic in Adults With Androgenetic Alopecia
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- BIONEER Corporation
- Participants (registry)
- 90
- Start
- December 2024
- Primary completion
- January 2026
- Study completion
- January 2026
- Last registry update
- October 2026
- Countries
- South Korea
Conditions studied: Androgenetic Alopecia
Interventions: Low-Concentration CosmeRNA-ARI Anti Hair Loss Tonic, High-Concentration CosmeRNA-ARI Anti Hair Loss Tonic, Vehicle Control Tonic Without CosmeRNA-AR
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.